genistein
GENISTEIN is an isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in Felmingia vestita, which is a plant traditionally used against worms. It has also been demonstrated to be effective against intestinal parasites such as the common liver fluke, pork trematode and poultry cestode. Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women. Genistein can be found in food sources such as tofu, fava beans, soybeans, kudzu, and lupin. It is also present in certain cell cultures and medicinal plants. — NCATS
Clinical trial activity
49 trials · 54 clinical orgs · 0 marketing orgs
Earliest trial started Apr 1, 1997 (NCT00000613)
Timeline
Indications
Approved for
Studied for
- Acute Radiation Syndrome · Phase 1
- Adenocarcinoma · Phase 1/Phase 2
- Bone Diseases · Phase 2
- Bone Diseases, Metabolic · Phase 2/Phase 3
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Cardiomyopathies · Phase 1/Phase 2
- Cardiovascular Diseases · Phase 2
- Child · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Coronary Artery Disease · Phase 2/Phase 3
- Coronary Disease · Phase 2
- COVID-19 · Phase 2
- Cystic Fibrosis · Phase 2
- Depression · Phase 2
- Endometrial Hyperplasia · Phase 2
- Endometrial Neoplasms · Phase 1
- Healthy Volunteers · Phase 1
- Heart Diseases · Phase 2
- Heart Failure · Phase 1/Phase 2
- Hodgkin Disease · Phase 2
- Kidney Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Medulloblastoma · Phase 2
- Melanoma · Phase 1/Phase 2
- Menopause · Phase 2/Phase 3
- Metabolic Syndrome · Phase 3
- Myocardial Ischemia · Phase 2
- Neoplasms · Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Neuroblastoma · Phase 2
- Neuroectodermal Tumors, Primitive · Phase 2
- Obesity · Phase 1/Phase 2
- Osteoporosis · Phase 2/Phase 3
- Pain · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 2
- Postmenopause · Phase 2
- Prostatic Neoplasms · Phase 2/Phase 3
- Pulmonary Fibrosis · Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 2
- Sepsis · Phase 4
- Urinary Bladder Neoplasms · Phase 2
- Wilms Tumor · Phase 2
Mechanism of action
- 78 kDa glucose-regulated proteinACTIVATOR
HSPA5 activator
Chemistry & pharmacology
SMILES
OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O- Mol. weight
- 270.2369 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGenistein ↗
- NCATSDH2M523P0H ↗
- ChEMBLCHEMBL44 ↗
Also known as
- 4',5, 7-trihydroxyisoflavone
- 4',5, 7-trihydroxyisoflavone
- 5,7,4'-trihydroxyisoflavone
- 5,7,4'-trihydroxyisoflavone
- genistein
- genistein
- genistein
- genisteine
- genisteine
- genisteol
- genisteol
- genisterin
- genisterin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07033767 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2025 | London Health Sciences Centre, University of Western Ontario |
| NCT06689566 | N/A | Dec 31, 2024 | National Taiwan University |
| NCT06741345 | Phase 1 | Dec 23, 2024 | Humanetics Corporation |
| NCT06895954 | N/A | Oct 13, 2024 | Southern Medical University |
| NCT06634108 | Phase 1/Phase 2 (Phase 2) | Sep 27, 2024 | Greenstone Biosciences, University of Western Ontario |
| NCT06501768 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2024 | Greenstone Biosciences, University of Ljubljana |
| NCT04650555 | Phase 1 | Dec 8, 2020 | Department of Defense, Humanetics Corporation, United States Army |
| NCT04482595 | Phase 2 | Nov 11, 2020 | Humanetics Corporation, National Institute of Allergy and Infectious Diseases (NIAID), New York University |
| NCT02766478 | Phase 2 | Aug 1, 2017 | Emory University |
| NCT01489813 | Phase 2 | May 19, 2017 | Emory University |
| NCT03040531 | Phase 2/Phase 3 (Phase 3) | Jan 19, 2017 | Government of Italy, University of Messina |
| NCT02624388 | Phase 2 | Aug 1, 2016 | University of Virginia |
| NCT02499861 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2015 | University of Montreal |
| NCT02796794 | Phase 4 | Jun 30, 2015 | Erciyes University |
| NCT01982578 | N/A | Nov 1, 2013 | University of Valencia |
| NCT01985763 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2013 | DSM, Icahn School of Medicine at Mount Sinai |
| NCT04105023 | N/A | Sep 15, 2013 | Government of Mexico, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| NCT01628471 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2012 | DSM, Pharmasciences |
| NCT01538316 | N/A | Mar 1, 2012 | Quercegen Pharmaceuticals, University of Hohenheim, University of Tuebingen |
| NCT01325311 | Phase 2 | Dec 1, 2011 | National Cancer Institute (NCI), University of Wisconsin |
Organizations
Research & Development (54)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 13 | 4 | 2 | 1998 |
| University of Messina | Academic/Hospital | 5 | 5 | 2 | 2003 |
| Northwestern University | Academic/Hospital | 4 | 3 | 2 | 2002 |
| Government of Italy | Government | 3 | 0 | 1 | 2007 |
| Humanetics Corporation | For profit | 3 | 3 | 2 | 2020 |
| Cystic Fibrosis Foundation Therapeutics | Academic/Hospital | 2 | 0 | 1 | 2001 |
| DSM | For profit | 2 | 0 | 1 | 2012 |
| Emory University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Greenstone Biosciences | For profit | 2 | 0 | 1 | 2024 |
| University of California, Davis | Academic/Hospital | 2 | 2 | 2 | 2003 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 2 | 2 | 1 | 1999 |
| University of Pennsylvania | Academic/Hospital | 2 | 2 | 1 | 2001 |
| University of Western Ontario | Academic/Hospital | 2 | 2 | 1 | 2024 |
| University of Wisconsin | Academic/Hospital | 2 | 0 | 1 | 2005 |
| Wayne State University | Academic/Hospital | 2 | 2 | 1 | 2004 |
| Axcentua Pharmaceuticals AB | For profit | 1 | 1 | 1 | 2010 |
| Chinese Nutrition Society | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Danone Research | For profit | 1 | 0 | 1 | 2009 |
| Department of Defense | Government | 1 | 0 | 1 | 2020 |
| Erciyes University | Academic/Hospital | 1 | 1 | 1 | 2015 |